Accord Healthcare Ltd, the principal European subsidiary of Intas Pharmaceuticals and the largest supplier by volume of generic medicines to the NHS, is collaborating on a large multi-national study into the prevention of COVID-19 infection using hydroxychloroquine, a drug that may have an effect in preventing and/or reducing symptoms of COVID-19, in line with the WHO’s targeted research priorities. The global COPCOV (chloroquine / hydroxychloroquine prevention of COVID-19 in the healthcare setting; a randomised, placebo-controlled prophylaxis) study involves 40,000 frontline healthcare workers who are caring for COVID-19 patients and is planned to start shortly.
COPCOV will be led by UK scientists from the University of Oxford and funded by the Wellcome Trust; the study pools the resources of international experts* across multiple continents. Accord will provide up to two million tablets of hydroxychloroquine to the trial, free of charge, along with two million tablets of matched placebo...
Full text GMPnews.Net